*Disseminated on Behalf of Quantum BioPharma Ltd.

Key Technicals Are Triggered As (Nasdaq: QNTM) Takes Control Of Friday’s Watchlist (Low Float)

August 7th

Greetings Readers,

There’s a company making notable progress in the ever-changing world of neuroscience and specialty pharmaceuticals.

Recently, they’ve achieved a series of significant clinical milestones, including the development of a novel oral therapy for multiple sclerosis that’s generating quite a bit of buzz in the medical community.

What makes this organization stand out is their blend of scientific innovation and strategic execution; their approach doesn’t just advance treatment, it also reflects a keen understanding of where the sector is headed.

Such qualities are drawing attention from experts and decision-makersthroughout heal-thcare, as the company continues to influence shifting trends in patient care and drug development.

For anyone closely following the evolving landscape of specialty pharmaceuticals, this is a company whose progress could certainly be worth exploring in greater detail.

And with a low float of fewer than 3Mn shares, a strong analyst target, multiple bullish technicals, and game-changing news in the recent term, this Nasdaq biopharma profile has taken over my watchlist:

*Quantum BioPharma Ltd. (Nasdaq: QNTM)*

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.

Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc.

And based on several potential catalysts, (Nasdaq: QNTM) has claimed the top spot on my watchlist. Check them out:

No. 1 – Volatility Potential Could Be Heightened Based On QNTM’s Low Float Structure.

No. 2 – A Multitude Of Bullish Technical Indicators May Help Analyze Market Trends.

No. 3 – A Strong Analyst Target Points To Double-Digit Potential Upside!

No. 4 – Positive Results Come Back In Key Clinical Study Report For Phase 1 Trial.

No. 5 – QNTM’s Subsidiary Completes Submission For An ILAP Passport (To Help Accelerate Clinical Development).

But more on those in a second…

(Nasdaq: QNTM) – Corporate Overview

Quantum BioPharma is an R&D focused biopharmaceutical company led by a world-class science team dedicated to building a portfolio of innovative assets and biotech solutions, with three near-term monetization events.

unbuzzd + rekvry

• unbuzzd™, a rapid alcohol detoxification beverage, the first-to-market with a scientifically formulated powder stick for this fast-growing consumer product category, launched in 2024 and expected to grow 300% by 2030
• REKVRY™ a formulation under development for an alcohol misuse treatment for use in emergency and hospital settings, an unmet need and has potential for exponential growth
• Owned by licensee Celly Nu – led by CPG market veterans with a proven track record of launching and scaling consumer product distribution programs while increasing company valuation by as much as 35-fold

LUCID MS

• LUCID MS – Potential multi-Bn asset in demyelinating diseases, with initial indication in multiple sclerosis (MS)
• Proprietary R&D conducted by a world-class team of medicinal chemists and pharmaceutical industry professionals

Portfolio Pipeline

Robust pipeline of products and assets focused on addressing significant unmet needs in brain disorders and alcohol health.

Revolutionary technology for alcohol intoxication, life-changing opp.

*Technology is currently patent-pending

Alcohol Misuse Treatment Upcoming Milestones

Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions.

Lucid-MS has shown excellent results in several animal models.

LUCID-MS: Disease Modifying Enabling Remyelination

A sampling of the novel qualities of Lucid-MS include:

• Excellent efficacy in various preclinical animal models
• Accelerates functional recovery of mouse models of Multiple Sclerosis, preserves myelin, and reduces zonal degradation
• Does not suppress immune system (non-immunomodulatory)
• Potential oral administration with easy dosing regimen

Quantum BioPharma has completed the dosing of healthy human volunteers for phase-1 clinical trials for Lucid-MS.

Today there is no cure for Multiple Sclerosis.

Quantum BioPharma (“QNTM”) is trying to change this for millions of people.

Grab Sources And More: QNTM Website. QNTM Presentation.

—–

And as I mentioned above, (Nasdaq: QNTM) has 5 potential breakout catalysts to consider. Take a look:

No. 1 QNTM Potential Catalyst – Volatility Potential Could Be Heightened Based On QNTM’s Low Float Structure.

According to info from the Yahoo Finance website, QNTM has a very low float.

The website reports this profile to have roughly 2.56Mn shares in its float.

Why is that important? It’s important on one crucial level. Volatility potential.

If positive company news appears in the midway part of 2025, could this low float potential help provide a breakout spark?

—–

No. 2 QNTM Potential Catalyst – A Multitude Of Bullish Technical Indicators May Help Analyze Market Trends.

On Thursday at 4:00PM EST, Barchart was reporting several triggered technical indicators across the short, medium, and long term for QNTM.

Here’s their list (as of 4:00PM EST Thursday):

Short Term Indicators

• 20 Day Moving Average
• 20 – 50 Day MA Crossover
• 20 – 100 Day MA Crossover
• 20 – 200 Day MA Crossover

Medium Term Indicators

• 50 Day Moving Average
• 50 – 100 Day MA Crossover
• 50 – 150 Day MA Crossover
• 50 – 200 Day MA Crossover

Long Term Indicators

• 100 Day Moving Average
• 150 Day Moving Average
• 200 Day Moving Average
• 100 – 200 Day MA Crossover

The website also shares its all-important “Trend Seeker” composite indicator is triggered as well.

Make sure to watch these technical indicators closely moving forward.

—–

No. 3 QNTM Potential Catalyst – A Strong Analyst Target Points To Double-Digit Potential Upside!

In June, an analyst with Singular Research bumped their target on QNTM up to $35.50.

From Thursday’s closing valuation at 4:00PM EST, this target provided QNTM with a potential upside of over 30%.

Here’s a highlight from the report:

We adjust our target price to $35.50 per share (earlier $12.90). Our new target price factors in contribution from FSD202 given that it is expected to start its Phase 2 trials soon. This is the main reason for the increase in our price target. We reiterate our BuyVenture rating with a capital price appreciation potential of 38%.

—–

No. 4 QNTM Potential Catalyst – Positive Results Come Back In Key Clinical Study Report For Phase 1 Trial.

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has received the clinical study report (CSR) for the trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-MS in Healthy Adult Participants.” The CSR concludes that there were no safety or tolerability concerns that were identifiedin healthy participants following treatment with consecutive daily dosing of Lucid-MS.

…

“We are thrilled that we now have the CSR for the Phase 1 MAD trial and that Lucid-MS was found to be safe and well-tolerated in healthy participants. The CSR allows us to advance the clinical development of Lucid-MS as it is a critical component of the investigational new drug (IND) application with the FDA,” said Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs at Quantum BioPharma.

“Results and observations from the first-in-human studies including this MAD investigation give us the confidence that Lucid-MS is safe and tolerable in healthy volunteers,” said Dr. Lakshmi P. Kotra, Director at Quantum BioPharma and a Professor at University of Toronto, who led the discovery of Lucid-MS.“Quantum team is preparing for the launch of efficacy trials in patients with MS which is very exciting. This compound follows a novel non-immunomodulatory mechanism, and we are very excited to be planning human efficacy trials.”

Read the full article here.

—–

No. 5 QNTM Potential Catalyst – QNTM’s Subsidiary Completes Submission For An ILAP Passport (To Help Accelerate Clinical Development).

Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., the submission of its patented candidate breakthrough drug, Lucid-21-302 (Lucid-MS), to the Innovative Licensing and Access Pathway (ILAP) Passport program in the United Kingdom (UK). The ILAP Passport application was submitted for Lucid-21-302 as a new, first-in-class treatment for multiple sclerosis (MS).

…

“We are excited to complete this submission for an ILAP Passport as this Program will help accelerate the clinical development of Lucid-21-302 as a new treatment for Multiple Sclerosis. Lucid-21-302 represents a new, patented, first-in-class treatment for MS targeting demyelination. We are excited about the possibility that the ILAP Program could accelerate drug development, regulatory approval and, most importantly, patient access to this exciting, new potential MS treatment in the UK,” said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.

Dr. Lakshmi P. Kotra, a Director at Quantum Biopharma, commented that, “our goal has always been to bring innovative drugs to patients as quickly as possible, and programs such as this in the UK are ideal avenues. At Quantum, we carefully and deliberately follow a well-thought-out global regulatory strategy to advance our clinical development efficiently, and as such we welcome partnerships with all stakeholders for better heal-thcare.”

Read the full article here.

—–

(Nasdaq: QNTM) Recap – 5 Potential Breakout Catalysts On Notice

No. 1 – Volatility Potential Could Be Heightened Based On QNTM’s Low Float Structure.

No. 2 – A Multitude Of Bullish Technical Indicators May Help Analyze Market Trends.

No. 3 – A Strong Analyst Target Points To Double-Digit Potential Upside!

No. 4 – Positive Results Come Back In Key Clinical Study Report For Phase 1 Trial.

No. 5 – QNTM’s Subsidiary Completes Submission For An ILAP Passport (To Help Accelerate Clinical Development).

—–

Coverage is now officially kicked-off on Quantum BioPharma Ltd. (Nasdaq: QNTM).

When updates are available, I’ll get them out quickly. Talk soon.

Sincerely,

Kai Parker

StockWireNews

(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.

Quantum BioPharma Ltd. (QNTM:US) (QNTM:CA) previously changed their company name and symbols from FSD Pharma Inc. (HUGE:US) (QNTM:CA)

Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 08/06/2025 and ending on 08/08/2025 to publicly disseminate information about (QNTM:US) (QNTM:CA) via digital communications. Under this agreement, SWN Media LLC has been paid twenty thousand USD (“Funds”). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred twenty seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Quantum BioPharma Ltd., the issuer of (QNTM:US) (QNTM:CA).

Neither SWN Media LLC, TD Media LLC and their member own shares of (QNTM:US) (QNTM:CA).

Please see important disclosure information here: https://stockwirenews.com/disclosure/qntm-txnsu/#details

*Disseminated on Behalf of Quantum BioPharma Ltd.

Nasdaq Biopharma Profile (QNTM) Takes Friday’s Radar By Storm (Low Float + Bullish Technicals)

August 7th

Dear Reader,

There’s a company making notable progress in the ever-changing world of neuroscience and specialty pharmaceuticals.

Recently, they’ve achieved a series of significant clinical milestones, including the development of a novel oral therapy for multiple sclerosis that’s generating quite a bit of buzz in the medical community.

What makes this organization stand out is their blend of scientific innovation and strategic execution; their approach doesn’t just advance treatment, it also reflects a keen understanding of where the sector is headed.

Such qualities are drawing attention from experts and decision-makers throughout heal-thcare, as the company continues to influence shifting trends in patient care and drug development.

For anyone closely following the evolving landscape of specialty pharmaceuticals, this is a company whose progress could certainly be worth exploring in greater detail.

And with a low float of fewer than 3Mn shares, a strong analyst target, multiple bullish technicals, and game-changing news in the recent term, this Nasdaq biopharma profile has taken over my watchlist:

*Quantum BioPharma Ltd. (Nasdaq: QNTM)*

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.

Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc.

And based on several potential catalysts, (Nasdaq: QNTM) has claimed the top spot on my watchlist. Check them out:

No. 1 – Volatility Potential Could Be Heightened Based On QNTM’s Low Float Structure.

No. 2 – A Multitude Of Bullish Technical Indicators May Help Analyze Market Trends.

No. 3 – A Strong Analyst Target Points To Double-Digit Potential Upside!

No. 4 – Positive Results Come Back In Key Clinical Study Report For Phase 1 Trial.

No. 5 – QNTM’s Subsidiary Completes Submission For An ILAP Passport (To Help Accelerate Clinical Development).

But more on those in a second…

(Nasdaq: QNTM) – Corporate Overview

Quantum BioPharma is an R&D focused biopharmaceutical company led by a world-class science team dedicated to building a portfolio of innovative assets and biotech solutions, with three near-term monetization events.

unbuzzd + rekvry

• unbuzzd™, a rapid alcohol detoxification beverage, the first-to-market with a scientifically formulated powder stick for this fast-growing consumer product category, launched in 2024 and expected to grow 300% by 2030
• REKVRY™ a formulation under development for an alcohol misuse treatment for use in emergency and hospital settings, an unmet need and has potential for exponential growth
• Owned by licensee Celly Nu – led by CPG market veterans with a proven track record of launching and scaling consumer product distribution programs while increasing company valuation by as much as 35-fold

LUCID MS

• LUCID MS – Potential multi-Bn asset in demyelinating diseases, with initial indication in multiple sclerosis (MS)
• Proprietary R&D conducted by a world-class team of medicinal chemists and pharmaceutical industry professionals

Portfolio Pipeline

Robust pipeline of products and assets focused on addressing significant unmet needs in brain disorders and alcohol health.

Revolutionary technology for alcohol intoxication, life-changing opp.

*Technology is currently patent-pending

Alcohol Misuse Treatment Upcoming Milestones

Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions.

Lucid-MS has shown excellent results in several animal models.

LUCID-MS: Disease Modifying Enabling Remyelination

A sampling of the novel qualities of Lucid-MS include:

• Excellent efficacy in various preclinical animal models
• Accelerates functional recovery of mouse models of Multiple Sclerosis, preserves myelin, and reduces zonal degradation
• Does not suppress immune system (non-immunomodulatory)
• Potential oral administration with easy dosing regimen

Quantum BioPharma has completed the dosing of healthy human volunteers for phase-1 clinical trials for Lucid-MS.

Today there is no cure for Multiple Sclerosis.

Quantum BioPharma (“QNTM”) is trying to change this for millions of people.

Grab Sources And More: QNTM Website. QNTM Presentation.

—–

And as I mentioned above, (Nasdaq: QNTM) has 5 potential breakout catalysts to consider. Take a look:

No. 1 QNTM Potential Catalyst – Volatility Potential Could Be Heightened Based On QNTM’s Low Float Structure.

According to info from the Yahoo Finance website, QNTM has a very low float.

The website reports this profile to have roughly 2.56Mn shares in its float.

Why is that important? It’s important on one crucial level. Volatility potential.

If positive company news appears in the midway part of 2025, could this low float potential help provide a breakout spark?

—–

No. 2 QNTM Potential Catalyst – A Multitude Of Bullish Technical Indicators May Help Analyze Market Trends.

On Thursday at 4:00PM EST, Barchart was reporting several triggered technical indicators across the short, medium, and long term for QNTM.

Here’s their list (as of 4:00PM EST Thursday):

Short Term Indicators

• 20 Day Moving Average
• 20 – 50 Day MA Crossover
• 20 – 100 Day MA Crossover
• 20 – 200 Day MA Crossover

Medium Term Indicators

• 50 Day Moving Average
• 50 – 100 Day MA Crossover
• 50 – 150 Day MA Crossover
• 50 – 200 Day MA Crossover

Long Term Indicators

• 100 Day Moving Average
• 150 Day Moving Average
• 200 Day Moving Average
• 100 – 200 Day MA Crossover

The website also shares its all-important “Trend Seeker” composite indicator is triggered as well.

Make sure to watch these technical indicators closely moving forward.

—–

No. 3 QNTM Potential Catalyst – A Strong Analyst Target Points To Double-Digit Potential Upside!

In June, an analyst with Singular Research bumped their target on QNTM up to $35.50.

From Thursday’s closing valuation at 4:00PM EST, this target provided QNTM with a potential upside of over 30%.

Here’s a highlight from the report:

We adjust our target price to $35.50 per share (earlier $12.90). Our new target price factors in contribution from FSD202 given that it is expected to start its Phase 2 trials soon. This is the main reason for the increase in our price target. We reiterate our BuyVenture rating with a capital price appreciation potential of 38%.

—–

No. 4 QNTM Potential Catalyst – Positive Results Come Back In Key Clinical Study Report For Phase 1 Trial.

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has received the clinical study report (CSR) for the trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-MS in Healthy Adult Participants.” The CSR concludes that there were no safety or tolerability concerns that were identified in healthy participants following treatment with consecutive daily dosing of Lucid-MS.

…

“We are thrilled that we now have the CSR for the Phase 1 MAD trial and that Lucid-MS was found to be safe and well-tolerated in healthy participants. The CSR allows us to advance the clinical development of Lucid-MS as it is a critical component of the investigational new drug (IND) application with the FDA,” said Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs at Quantum BioPharma.

“Results and observations from the first-in-human studies including this MAD investigation give us the confidence that Lucid-MS is safe and tolerable in healthy volunteers,” said Dr. Lakshmi P. Kotra, Director at Quantum BioPharma and a Professor at University of Toronto, who led the discovery of Lucid-MS. “Quantum team is preparing for the launch of efficacy trials in patients with MS which is very exciting. This compound follows a novel non-immunomodulatory mechanism, and we are very excited to be planning human efficacy trials.”

Read the full article here.

—–

No. 5 QNTM Potential Catalyst – QNTM’s Subsidiary Completes Submission For An ILAP Passport (To Help Accelerate Clinical Development).

Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., the submission of its patented candidate breakthrough drug, Lucid-21-302 (Lucid-MS), to the Innovative Licensing and Access Pathway (ILAP) Passport program in the United Kingdom (UK). The ILAP Passport application was submitted for Lucid-21-302 as a new, first-in-class treatment for multiple sclerosis (MS).

…

“We are excited to complete this submission for an ILAP Passport as this Program will help accelerate the clinical development of Lucid-21-302 as a new treatment for Multiple Sclerosis. Lucid-21-302 represents a new, patented, first-in-class treatment for MS targeting demyelination. We are excited about the possibility that the ILAP Program could accelerate drug development, regulatory approval and, most importantly, patient access to this exciting, new potential MS treatment in the UK,” said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.

Dr. Lakshmi P. Kotra, a Director at Quantum Biopharma, commented that, “our goal has always been to bring innovative drugs to patients as quickly as possible, and programs such as this in the UK are ideal avenues. At Quantum, we carefully and deliberately follow a well-thought-out global regulatory strategy to advance our clinical development efficiently, and as such we welcome partnerships with all stakeholders for better heal-thcare.”

Read the full article here.

—–

(Nasdaq: QNTM) Recap – 5 Potential Breakout Catalysts On Notice

No. 1 – Volatility Potential Could Be Heightened Based On QNTM’s Low Float Structure.

No. 2 – A Multitude Of Bullish Technical Indicators May Help Analyze Market Trends.

No. 3 – A Strong Analyst Target Points To Double-Digit Potential Upside!

No. 4 – Positive Results Come Back In Key Clinical Study Report For Phase 1 Trial.

No. 5 – QNTM’s Subsidiary Completes Submission For An ILAP Passport (To Help Accelerate Clinical Development).

—–

Coverage is now officially kicked-off on Quantum BioPharma Ltd. (Nasdaq: QNTM).

When updates are available, I’ll get them out quickly. Talk soon.

Sincerely,

FierceAnalyst | Jaks Swift

Editorial Writer

(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor (“FI”) is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.

Quantum BioPharma Ltd. (QNTM:US) (QNTM:CA) previously changed their company name and symbols from FSD Pharma Inc. (HUGE:US) (QNTM:CA)

Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 08/06/2025 and ending on 08/08/2025 to publicly disseminate information about (QNTM:US) (QNTM:CA) via digital communications. Under this agreement, SWN Media LLC has been paid twenty thousand USD (“Funds”). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred twenty seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Quantum BioPharma Ltd., the issuer of (QNTM:US) (QNTM:CA).

Neither SWN Media LLC, TD Media LLC and their member own shares of (QNTM:US) (QNTM:CA).

Please see important disclosure information here: https://fierceinvestor.com/disclosure/qntm-txnsu/#details